within Pharmacolibrary.Drugs.ATC.A;

model A10BH08
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.536,
    Cl             = 0.0006149999999999999,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.294,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.024,
    Tlag           = 19.8,            
    Vdp             = 0.0742,
    k12             = 44.2,
    k21             = 44.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BH08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Teneligliptin is an oral, selective dipeptidyl peptidase-4 (DPP-4) inhibitor used in the treatment of type 2 diabetes mellitus. It works by increasing incretin levels, which inhibit glucagon release and increase insulin secretion, thereby lowering blood glucose levels. Teneligliptin is approved and widely used in several countries, including Japan and India, for glycemic control in adults with type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after a single oral dose of 20 mg teneligliptin under fasting conditions.</p><h4>References</h4><ol><li><p>Halabi, A, et al., &amp; Hinrichsen, H (2014). Pharmacokinetics and safety of teneligliptin in subjects with hepatic impairment. <i>Clinical pharmacology in drug development</i> 3(4) 290–296. DOI:<a href=\"https://doi.org/10.1002/cpdd.89\">10.1002/cpdd.89</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27128835/\">https://pubmed.ncbi.nlm.nih.gov/27128835</a></p></li><li><p>Scott, LJ (2015). Teneligliptin: a review in type 2 diabetes. <i>Clinical drug investigation</i> 35(11) 765–772. DOI:<a href=\"https://doi.org/10.1007/s40261-015-0348-9\">10.1007/s40261-015-0348-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26475720/\">https://pubmed.ncbi.nlm.nih.gov/26475720</a></p></li><li><p>Halabi, A, et al., &amp; Klause, N (2013). Pharmacokinetics of Teneligliptin in Subjects With Renal Impairment. <i>Clinical pharmacology in drug development</i> 2(3) 246–254. DOI:<a href=\"https://doi.org/10.1002/cpdd.29\">10.1002/cpdd.29</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27121786/\">https://pubmed.ncbi.nlm.nih.gov/27121786</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BH08;
